Claim: Intranasal CAX is a peptide that was originally studied in Russia and has been found to improve outcomes after traumatic brain injury and stroke.
Verdict: Unverified (45% confidence)
Explanation: The claim remains unverified due to the absence of credible sources that specifically support the core elements of the claim regarding CAX. While the available sources discuss intranasal delivery systems and peptides in general, they do not confirm the specific claims about CAX being a peptide, its study origin in Russia, or its effectiveness in improving outcomes after traumatic brain injury and stroke. Therefore, the claim is unverified due to the lack of direct evidence.